An interventional study of exendin(9-39)amide and Saline (0.9% NaCl) in Type 1 Diabetes, sponsored by Asger Lund, MD. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Asger Lund, MD · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 128th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2026, is one of 83 with no phase, and was the 187th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 2–18
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Klavs Würgler Hansen · Sites in Denmark
Ages 18+
Henrik Bo Wiberg Larsson · Sites in Denmark, Germany
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
196 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 34 · Phase 4 19
First in 1995; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 157 interventional studies, 175 across the 38 observational. Of the 147 that completed or were terminated, 28 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 196 have an industry lead sponsor. The 10 most frequent:
Asger Lund, MD is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Asger Lund, MD has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 1 with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07247734Asger Lund, MDThe Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation | 2026-12-22 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
Add all 11 to your calendar (.ics) → With an account.
Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Type 1 diabetes is a serious and burdensome disease that carries the risk of severe complications and premature death, partly due to low blood sugar, also called hypoglycaemia. This is a constant threat, as individuals with type 1 diabetes lack the body's natural safeguard against low blood sugar: the hormone glucagon, which is normally released from the pancreas.
Recent research in mice suggests that this missing safeguard may be due to an imbalance in the hormones released from different cells in the pancreas. More specifically, glucagon-like peptide-1 (GLP-1) appears to play a role in the lack of glucagon secretion. By blocking this hormone using the substance exendin(9-39)NH₂, normalization of glucagon release during low blood sugar has been observed in mice with type 1 diabetes.
The present study aims to investigate whether the same mechanism applies in humans with type 1 diabetes. If confirmed, this finding could form the basis for a novel adjunct treatment to insulin therapy and thereby potentially reduce the risk of hypoglycaemia in this patient group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLP-1 antagonist
Drug: exendin(9-39)amide
Saline
Drug: Saline (0.9% NaCl)
GLP-1 antagonist
Placebo
Also known as: Placebo
bsAUC Glucagon
Entire study periode
Time frame: 0-135 minutes
bsAUC of Glucagon
Primary endpoint
Time frame: 30-90 minutes
Total Glucose infused
Recovery phase glucose infused
Time frame: 90-135 minutes
Glucose infused (entire period)
Entire glucose infused
Time frame: 0-135 minutes
GLP-1
Circulating GLP-1
Time frame: 0-135 minutes
Cortisol
Cortisol
Time frame: 0-135 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Apr 2026, 2 months.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 2 months is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avexitide
Asger Lund, MD